BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET
Company Participants
John Bluth - Chief Communications Officer
Jon Stonehouse - CEO
Charlie Gayer - Chief Commercial Officer
Helen Thackray - Chief R&D Officer
Conference Call Participants
Steven Seedhouse - Cantor
Maury Raycroft - Jefferies
Jessica Fye - JP Morgan
Stacy Ku - TD Cowen
Gena Wang - Barclays
Laura Chico - Wedbush Securities
Liisa Bayko - Evercore ISI
Serge Belanger - Needham & Co.
Jonathan Wolleben - Citizens JMP
Operator
Good day, and welcome to the BioCryst First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note that this event is being recorded.
I would now like to turn the conference over to John Bluth with Investor Relations with BioCryst. Please go ahead.
John Bluth
Thank you. Good morning, and welcome to BioCryst's First Quarter 2025 Corporate Update and Financial Results Conference Call. Today's press release and accompanying slides are available on our website.
Participating with me today are CEO, Jon Stonehouse; Chief Commercial Officer, Charlie Gayer; and Chief R&D Officer, Dr. Helen Thackray. Following our remarks, we will answer your questions.
Today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our
- Read more current BCRX analysis and news
- View all earnings call transcripts